Day One Biopharmaceuticals (DAWN) Competitors $6.99 -0.12 (-1.69%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$7.10 +0.11 (+1.56%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. RARE, TLX, NAMS, VKTX, XENE, AMRX, SRRK, IMVT, MOR, and HCMShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include Ultragenyx Pharmaceutical (RARE), Telix Pharmaceuticals (TLX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), AMNEAL PHARMACEUTICALS (AMRX), Scholar Rock (SRRK), Immunovant (IMVT), MorphoSys (MOR), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. Its Competitors Ultragenyx Pharmaceutical Telix Pharmaceuticals NewAmsterdam Pharma Viking Therapeutics Xenon Pharmaceuticals AMNEAL PHARMACEUTICALS Scholar Rock Immunovant MorphoSys HUTCHMED Day One Biopharmaceuticals (NASDAQ:DAWN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends. Does the media prefer DAWN or RARE? In the previous week, Ultragenyx Pharmaceutical had 8 more articles in the media than Day One Biopharmaceuticals. MarketBeat recorded 9 mentions for Ultragenyx Pharmaceutical and 1 mentions for Day One Biopharmaceuticals. Day One Biopharmaceuticals' average media sentiment score of 1.81 beat Ultragenyx Pharmaceutical's score of 1.12 indicating that Day One Biopharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Day One Biopharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ultragenyx Pharmaceutical 6 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer DAWN or RARE? Day One Biopharmaceuticals presently has a consensus target price of $25.29, indicating a potential upside of 261.74%. Ultragenyx Pharmaceutical has a consensus target price of $81.50, indicating a potential upside of 183.87%. Given Day One Biopharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Day One Biopharmaceuticals is more favorable than Ultragenyx Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Ultragenyx Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Is DAWN or RARE more profitable? Day One Biopharmaceuticals has a net margin of -50.63% compared to Ultragenyx Pharmaceutical's net margin of -87.34%. Day One Biopharmaceuticals' return on equity of -19.01% beat Ultragenyx Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Day One Biopharmaceuticals-50.63% -19.01% -16.99% Ultragenyx Pharmaceutical -87.34%-237.48%-37.66% Which has more risk and volatility, DAWN or RARE? Day One Biopharmaceuticals has a beta of -1.25, suggesting that its share price is 225% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Which has stronger valuation and earnings, DAWN or RARE? Day One Biopharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$131.16M5.46-$95.50M-$0.95-7.36Ultragenyx Pharmaceutical$560.23M4.94-$569.18M-$5.53-5.19 Do institutionals & insiders believe in DAWN or RARE? 88.0% of Day One Biopharmaceuticals shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 6.2% of Day One Biopharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryDay One Biopharmaceuticals beats Ultragenyx Pharmaceutical on 11 of the 17 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DAWN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$728.29M$3.12B$5.74B$10.30BDividend YieldN/A2.37%5.89%4.62%P/E Ratio-7.3621.0376.6926.52Price / Sales5.46249.02444.6987.66Price / CashN/A45.4837.2260.63Price / Book1.409.5613.596.31Net Income-$95.50M-$53.02M$3.29B$271.37M7 Day Performance-5.16%-1.41%-0.69%0.59%1 Month Performance2.64%2.98%3.85%6.22%1 Year Performance-49.31%9.49%81.84%28.35% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals3.0052 of 5 stars$6.99-1.7%$25.29+261.7%-49.2%$728.29M$131.16M-7.3660Positive NewsRAREUltragenyx Pharmaceutical4.3152 of 5 stars$31.51-1.0%$81.50+158.6%-50.9%$3.07B$560.23M-5.701,294TLXTelix Pharmaceuticals3.6374 of 5 stars$9.05-0.1%$22.33+146.8%N/A$3.07B$516.72M0.00N/ANAMSNewAmsterdam Pharma3.0548 of 5 stars$25.09-7.1%$41.55+65.6%+58.5%$3.04B$45.56M-15.494Positive NewsHigh Trading VolumeVKTXViking Therapeutics4.1766 of 5 stars$25.48-5.6%$86.92+241.1%-63.3%$3.03BN/A-16.6520XENEXenon Pharmaceuticals2.4057 of 5 stars$38.19-2.6%$53.30+39.6%-8.5%$3.02B$9.43M-10.76210Positive NewsOptions VolumeAMRXAMNEAL PHARMACEUTICALS3.4444 of 5 stars$9.73+1.1%$11.60+19.2%+8.8%$3.02B$2.79B973.978,100Positive NewsAnalyst ForecastSRRKScholar Rock4.4522 of 5 stars$31.58+0.5%$45.75+44.9%+287.7%$3.02B$33.19M-10.85140Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionGap UpIMVTImmunovant2.3275 of 5 stars$16.37-4.5%$33.60+105.3%-48.0%$2.99BN/A-5.74120Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730HCMHUTCHMED2.6666 of 5 stars$16.11+0.9%$28.00+73.8%+7.2%$2.79B$630.20M0.001,811 Related Companies and Tools Related Companies Ultragenyx Pharmaceutical Competitors Telix Pharmaceuticals Competitors NewAmsterdam Pharma Competitors Viking Therapeutics Competitors Xenon Pharmaceuticals Competitors AMNEAL PHARMACEUTICALS Competitors Scholar Rock Competitors Immunovant Competitors MorphoSys Competitors HUTCHMED Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTen Bucks, Five Minutes... Could Send You Up to $8K QUARTERLYDOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredWhy Peter Thiel Hid Gold in a VaultSilicon Valley billionaires hiding gold in vaults? Peter Thiel’s Palantir quietly diverted tens of millions...Golden Portfolio | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
